Pregled bibliografske jedinice broj: 88260
Cerebrospinal fluid and serum soluble glycoprotein 130 (sgp130 levels) in patients with relapsing-remitting multiple sclerosis
Cerebrospinal fluid and serum soluble glycoprotein 130 (sgp130 levels) in patients with relapsing-remitting multiple sclerosis // Neurologia Croatica
Zagreb: UNIV HOSPITAL ZAGREB, SCHOOL MEDICINE, 2001. str. 33-33 (poster, međunarodna recenzija, sažetak, znanstveni)
CROSBI ID: 88260 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Cerebrospinal fluid and serum soluble glycoprotein 130 (sgp130 levels) in patients with relapsing-remitting multiple sclerosis
Autori
Horvat, Gordana ; Vladić, Anton ; Zadro, Ivana ; Vukadin, Stipe ; Čulo, Filip
Vrsta, podvrsta i kategorija rada
Sažeci sa skupova, sažetak, znanstveni
Izvornik
Neurologia Croatica
/ - Zagreb : UNIV HOSPITAL ZAGREB, SCHOOL MEDICINE, 2001, 33-33
Skup
1st Dubrovnik International Conference on Multiple Sclerosis
Mjesto i datum
Dubrovnik, Hrvatska, 09.05.2001. - 12.05.2001
Vrsta sudjelovanja
Poster
Vrsta recenzije
Međunarodna recenzija
Ključne riječi
gp130; CSF; serum; multiple sclerosis
Sažetak
Introduction: Glycoprotein 130 is a signal-transducing receptor subunit of the proinflammatory cytokine inteleukin-6, which is implicated in the pathogenesis of multiple sclerosis (MS). Soluble form of gp130 (sgp130) can be found in human serum. The aim of this study was to measure the sgp130 in the cerebrospinal fluid (CSF) and serum from relapsing-remitting MS patients during acute exacerbation of the disease. Patients and methods: We analysed CSF and serum samples of 17 relapsing-remitting MS patients during acute exacerbation of the disease and 15 patients with noninflammatory neurological diseases (NIND). Sgp130 levels were measured using specific enzymeimmuno test (ELISA). One-way ANOVA was applied for statistical analysis of the data. Results: Our preliminary results show that there is no significant difference in the levels of sgp130 in CSF and serum between MS and NIND patients. Conclusion: These preliminary results indicate that sgp130 might not be the marker of the acute MS exacerbation.
Izvorni jezik
Engleski